Nature Communications (Mar 2021)
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
- Bénedith Oben,
- Guy Froyen,
- Kylee H. Maclachlan,
- Daniel Leongamornlert,
- Federico Abascal,
- Binbin Zheng-Lin,
- Venkata Yellapantula,
- Andriy Derkach,
- Ellen Geerdens,
- Benjamin T. Diamond,
- Ingrid Arijs,
- Brigitte Maes,
- Kimberly Vanhees,
- Malin Hultcrantz,
- Elisabet E. Manasanch,
- Dickran Kazandjian,
- Alexander Lesokhin,
- Ahmet Dogan,
- Yanming Zhang,
- Aneta Mikulasova,
- Brian Walker,
- Gareth Morgan,
- Peter J. Campbell,
- Ola Landgren,
- Jean-Luc Rummens,
- Niccolò Bolli,
- Francesco Maura
Affiliations
- Bénedith Oben
- Lab. Experimental Hematology, Dept. Clinical Biology, Jessa Hospital
- Guy Froyen
- Faculty of Medicine and Life Sciences, Hasselt University
- Kylee H. Maclachlan
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Daniel Leongamornlert
- The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute
- Federico Abascal
- The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute
- Binbin Zheng-Lin
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Venkata Yellapantula
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Andriy Derkach
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
- Ellen Geerdens
- Lab. Molecular Diagnostics, Dept. Clinical Biology, Jessa Hospital
- Benjamin T. Diamond
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Ingrid Arijs
- Faculty of Medicine and Life Sciences, Hasselt University
- Brigitte Maes
- Lab. Molecular Diagnostics, Dept. Clinical Biology, Jessa Hospital
- Kimberly Vanhees
- Faculty of Medicine and Life Sciences, Hasselt University
- Malin Hultcrantz
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Elisabet E. Manasanch
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center
- Dickran Kazandjian
- Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
- Alexander Lesokhin
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Ahmet Dogan
- Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center
- Yanming Zhang
- Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center
- Aneta Mikulasova
- Biosciences Institute, Faculty of Medical Sciences, Newcastle University
- Brian Walker
- Division of Hematology Oncology, School of Medicine, Indiana University
- Gareth Morgan
- Perlmutter Cancer Center, New York University Langone Health
- Peter J. Campbell
- The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute
- Ola Landgren
- Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami
- Jean-Luc Rummens
- Lab. Experimental Hematology, Dept. Clinical Biology, Jessa Hospital
- Niccolò Bolli
- Department of Oncology and Hemato-Oncology, University of Milan
- Francesco Maura
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-021-22140-0
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
The factors that are associated with myeloma precursor condition progression are not well understood. Here the authors find that monoclonal gammopathies of undetermined significance and smoldering myelomas that did not progress to multiple myelomas have a distinct genomic profile and emerge later in the patient’s life.
